New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.